Participant flow

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma · Source last updated 2026-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive melphalan, prednisone and thalidomide induction plus thalidomide maintenance (MPT-T). INDUCTION THERAPY: Patients receive melphalan 9 mg/m\^2 PO and prednisone 100 mg PO daily on days 1-4, and thalidomide 100 mg PO daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY: Patients receive thalidomide 100 mg PO daily and continue in the absence of disease progression.

   id

   FG000

   title

   Arm I (MPT-T)

2. description

   Patients receive lower-dose melphalan, prednisone and lenalidomide (Revlimid®) induction plus lenalidomide maintenance (mPR-R). INDUCTION THERAPY: Patients receive melphalan 5 mg/m\^2 PO and prednisone 100 mg PO daily on days 1-4, and lenalidomide 10 mg PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY: Patients receive lenalidomide 10 mg PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression.

   id

   FG001

   title

   Arm II (mPR-R)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         6

      2. group Id

         FG001

         num Subjects

         2

      type

      Never started protocol therapy

   2. reasons

      1. group Id

         FG000

         num Subjects

         8

      2. group Id

         FG001

         num Subjects

         15

      type

      Still on treatment at time of analysis

   3. reasons

      1. group Id

         FG000

         num Subjects

         62

      2. group Id

         FG001

         num Subjects

         53

      type

      Adverse Event

   4. reasons

      1. group Id

         FG000

         num Subjects

         38

      2. group Id

         FG001

         num Subjects

         55

      type

      Disease progression

   5. reasons

      1. group Id

         FG000

         num Subjects

         6

      2. group Id

         FG001

         num Subjects

         5

      type

      Death

   6. reasons

      1. group Id

         FG000

         num Subjects

         15

      2. group Id

         FG001

         num Subjects

         12

      type

      Withdrawal by Subject

   7. reasons

      1. group Id

         FG000

         num Subjects

         5

      2. group Id

         FG001

         num Subjects

         2

      type

      Alternative therapy

   8. reasons

      1. group Id

         FG000

         num Subjects

         5

      2. group Id

         FG001

         num Subjects

         2

      type

      Other Complicating Disease

   9. reasons

      1. group Id

         FG000

         num Subjects

         5

      2. group Id

         FG001

         num Subjects

         4

      type

      Physician Decision

   10. reasons

       1. group Id

          FG000

          num Subjects

          1

       2. group Id

          FG001

          num Subjects

          1

       type

       Administrative Closure

   11. reasons

       1. group Id

          FG000

          num Subjects

          3

       2. group Id

          FG001

          num Subjects

          1

       type

       Other

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         154

      2. group Id

         FG001

         num Subjects

         152

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         148

      2. group Id

         FG001

         num Subjects

         150

      type

      Started Protocol Therapy

   3. achievements

      1. comment

         Treatment continued until progression of disease, unacceptable toxicity or patient withdrawal.

         group Id

         FG000

         num Subjects

         0

      2. comment

         Treatment continued until progression of disease, unacceptable toxicity or patient withdrawal.

         group Id

         FG001

         num Subjects

         0

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         154

      2. group Id

         FG001

         num Subjects

         152

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

The study was activated on February 29, 2008 and closed to accrual on November 30, 2011 with final accrual of 306 patients.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice